[Topics of neuromyelitis optica].
Neuromyelitis optica (NMO) has been revealed the difference in the pathology of multiple sclerosis since the anti-aquaporin 4 (AQP4) antibody associated with NMO has been found. The clinical epidemiological study has been reviewed, NMO-related patient number in Japan is estimated to be about 4400 people. The antibody-positive patients against myelin-oligodendrocyte glycoprotein (MOG) are present in anti-AQP4 antibody-negative NMO patients. These patients have a characteristic with high frequency of optic neuritis and good response to therapy. In addition, by research in recent years, a new treatment such as anti-IL-6 therapy or anti-complement therapy has been attempted to NMO.
Department of Neurology, Kinki University School of Medicine.
Katsuichi
K
Miyamoto
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D051401:Aquaporin 4 / Q000276:immunology; D001323:Autoantibodies; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007564:Japan / Q000453:epidemiology; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D058990:Molecular Targeted Therapy; D009471:Neuromyelitis Optica / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D011239:Prednisolone / Q000008:administration & dosage; D020551:Pulse Therapy, Drug; D012008:Recurrence; D000069283:Rituximab; D012737:Sex Factors
C496030:AQP4 protein, human; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D051401:Aquaporin 4; D001323:Autoantibodies; D007166:Immunosuppressive Agents; D000069283:Rituximab; D011239:Prednisolone; C481642:eculizumab; C502936:tocilizumab; D008775:Methylprednisolone